Replimune Won Accelerated Approval on 91 Evaluable Patients and a 24% Response Rate
CBER took a 24% response in 91 evaluable patients, one day after the same committee voted nine to three against Capricor. Measurement, not size.
PD-1
The EPO Revoked BMS’s 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight
BMS claimed a 480mg flat dose. The only clinical example in its filed application dosed by weight. The EPO revoked the patent on added matter.
OncoC4 merged with AcroImmune
OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more